Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Bevacizumab

1 Open Trial

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCGIP1520

07/21/2015

A Phase 1, Open Label, Non Randomized, Dose Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS 102 in Combination with CPT 11 and Bevacizumab In Patients with Advanced Gastrointestinal Tumors